Injectable In Situ-Forming Hydrogels for Protein and Peptide Delivery

Park, Seung Hun; Ji, Yun Bae; Park, Joon Yeong; Ju, Hyeon Jin; Lee, Mijeong; Lee, Surha; Kim, Jae Ho; Min, Byoung Hyun; Kim, Moon Suk

doi:10.1007/978-981-15-3262-7_3

Cited by 3 publications

(2 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the administration of chemotherapeutic compounds via intratumoral injection could greatly reduce the amount of a drug required for a single administration compared with conventional approaches in which anticancer drugs are repeatedly administered (Figure 2). Therefore, the injectable in situ-forming hydrogels described in the previous sections can easily be prepared as anticancer drug-loaded hydrogel formulations and could be highly effective as a non-invasive method to treat cancer via direct intratumoral injection [75,76]. Tables 1 and 2 summarize a selection of recent studies that evaluated the applicability of anticancer drug-loaded in situ-forming hydrogels for intratumoral injection, which will be described in the following section.…”

Section: Intratumoral Injection Using Anticancer Drug-loaded Injectable Hydrogelsmentioning

confidence: 99%

Advances in Injectable In Situ-Forming Hydrogels for Intratumoral Treatment

Shin

Kim

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Chemotherapy has been linked to a variety of severe side effects, and the bioavailability of current chemotherapeutic agents is generally low, which decreases their effectiveness. Therefore, there is an ongoing effort to develop drug delivery systems to increase the bioavailability of these agents and minimize their side effects. Among these, intratumoral injections using in situ-forming hydrogels can improve drugs’ bioavailability and minimize drugs’ accumulation in non-target organs or tissues. This review describes different types of injectable in situ-forming hydrogels and their intratumoral injection for cancer treatment, after which we discuss the antitumor effects of intratumoral injection of drug-loaded hydrogels. This review concludes with perspectives on the future applicability of, and challenges for, the adoption of this drug delivery technology.

show abstract

Section: Intratumoral Injection Using Anticancer Drug-loaded Injectable Hydrogelsmentioning

confidence: 99%

Advances in Injectable In Situ-Forming Hydrogels for Intratumoral Treatment

Shin

Kim

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, multiple rounds of peptide doses are required to sustain their effect for which precise patient adherence is needed to achieve successful therapeutic outcomes. To reduce administration frequency and sustain desirable peptide levels, controlled peptide delivery devices have been investigated including the use of injectable hydrogels and implantable constructs, often made from degradable polymers [203,204].…”

Section: Introductionmentioning

confidence: 99%

Novel biomaterials for controlled immunomodulatory drug delivery

Wang¹

View full text Add to dashboard Cite

[EMBARGOED UNTIL 6/1/2023] With the success of solid organ transplantation, a next generation approach has been developed known as vascularized composite allografts which requires the transplantation of a whole functional unit comprised of many tissues including skin, bone, muscles, blood vessels, and nerves as a single unit from a deceased donor to the patient. However, similar to other solid organ transplants, the biggest challenge associated with vascularized composite allografts is their post-surgery acute rejection. To prevent and alleviate this problem, broad-spectrum immunosuppressants are required which unfortunately have two major disadvantages: (1) low on-target efficiency and/or severe adverse side effects and (2) require conventional oral and subcutaneous administration routes that can lead to systemic immunosuppression, which together increase the risk of infection or developing cancer. To address the first problem, I studied a promising biocompatible and immunomodulatory biologic -- vasoactive intestinal peptide and designed vasoactive intestinal peptide amphiphile micelles with different chemical formulations, shapes, and sizes to determine factors that influence the bioactivity of this peptide therapeutic. While specifically important for the development of novel immunosuppressant therapies, the impact micellar physical properties have on incorporated bioactive peptides determined from this research will help us continue to understand structure-function relationships more broadly for nanoparticle-based drug delivery systems. To avoid the undesirable systemic effects induced by oral administration or subcutaneous injection of immunosuppressants, I have designed a novel polyester hydrogel drug delivery device capable of achieving localized and controllable delivery of thiol-containing immunomodulatory peptides. Glutathione was used as a candidate therapeutic to test this system for which the hydrophilicity of the polymer backbone was modulated to achieve sustained drug release over six to ten days.

show abstract

The Antimicrobial, Hemostatic, and Anti‐Adhesion Effects of a Peptide Hydrogel Constructed by the All‐d‐Enantiomer of Antimicrobial Peptide Jelleine‐1

Zhang

Zhou

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Peptide hydrogels were believed to be potential biomaterials with wide application in the biomedical field because of their good biocompatibility, injectability, and three‐dimensional (3D) printability. Most of the previously reported polypeptide hydrogels are composed of L‐peptides, while the hydrogels formed by self‐assembly of D‐peptides are rarely reported. Herein, we reported a peptide hydrogel constructed by D‐J‐1, which was the all‐D‐enantiomer of antimicrobial peptide Jelleine‐1. Field emission scanning electron microscope (FE‐SEM) and rheologic study were performed to characterize the hydrogel. Antimicrobial, hemostatic, and anti‐adhesion studies were carried out to evaluate its biofunction. Our results showed that D‐J‐1 hydrogel was formed by self‐assembly and cross‐linking driven by hydrogen bonding, hydrophobic interaction, and π‐π stacking force of aromatic ring in the structure of D‐J‐1. It exhibited promising antimicrobial activity, hemostatic activity, and anti‐adhesion efficiency in a rat sidewall defect‐cecum abrasion model. In addition, it also exhibited good biocompatibility. Notably, D‐J‐1 hydrogel showed improved in vitro and in vivo stability when compared with its L‐enantiomer J‐1 hydrogel. Therefore, the present study would provide new insight into the application of D‐peptide hydrogel, and provide a new peptide hydrogel with antibacterial, hemostatic, and anti‐adhesion efficacy for clinical use.This article is protected by copyright. All rights reserved

show abstract

Injectable In Situ-Forming Hydrogels for Protein and Peptide Delivery

Cited by 3 publications

References 110 publications

Advances in Injectable In Situ-Forming Hydrogels for Intratumoral Treatment

Advances in Injectable In Situ-Forming Hydrogels for Intratumoral Treatment

Novel biomaterials for controlled immunomodulatory drug delivery

The Antimicrobial, Hemostatic, and Anti‐Adhesion Effects of a Peptide Hydrogel Constructed by the All‐d‐Enantiomer of Antimicrobial Peptide Jelleine‐1

Contact Info

Product

Resources

About